Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(25%)
Results Posted
150%(6 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
4
50%
Ph not_applicable
1
13%
Ph phase_2
2
25%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
2(28.6%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (57.1%)
Phase 22 (28.6%)
N/A1 (14.3%)

Trials by Status

completed450%
terminated225%
active_not_recruiting225%

Recent Activity

2 active trials
Showing 5 of 8
active_not_recruitingphase_2

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

NCT02675829
active_not_recruitingnot_applicable

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

NCT02226276
completedphase_2

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

NCT01494662
completedphase_1

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

NCT03364348
terminatedphase_1

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

NCT04296942
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02675829Phase 2

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Active Not Recruiting
NCT02226276Not Applicable

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Active Not Recruiting
NCT01494662Phase 2

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Completed
NCT03364348Phase 1

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Completed
NCT04296942Phase 1

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Terminated
NCT02038010Phase 1

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

Completed
NCT02318901Phase 1

Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer

Terminated
NCT00833963

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8